Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing
Medeiros BC, Possick J, Fradley M. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. Blood Reviews 2018, 32: 289-299. PMID: 29454474, DOI: 10.1016/j.blre.2018.01.004.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic myeloid leukemiaTyrosine kinase inhibitorsComorbid risk factorsMyeloid leukemiaTyrosine kinase inhibitor therapyPatients' disease profilesTreatment-limiting complicationsAdverse event profileKinase inhibitor therapyTKI selectionInhibitor therapyPrompt managementEvent profileTKI agentsCML treatmentPulmonary disordersPulmonary toxicityRisk factorsToxicity profileMyeloproliferative neoplasmsSymptoms of toxicityDisease profileMetabolic toxicityKinase inhibitorsAppropriate agent
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply